Status:
COMPLETED
Arm Spasticity - Non-Interventional Study Early BIRD (BoNT Treatment: Initial and Repeated Documentation)
Lead Sponsor:
Ipsen
Conditions:
Post-stroke Arm Spasticity
Eligibility:
All Genders
25+ years
Brief Summary
Botulinum toxin A (BoNT-A) is effective and safe in alleviating post-stroke spasticity and reducing the burden of associated symptoms. The hypothesis for this non-interventional study in arm spastici...
Eligibility Criteria
Inclusion
- Written informed consent prior to data collection
- Hemiparesis and clinically relevant upper limb post-stroke spasticity
- Treated with Dysport® or with the intention to be treated with Dysport® according to local SmPC
- BoNT naïve or pre-treated with any BoNT product
Exclusion
- Recurrent stroke
- Sensitivity to Dysport® or to its excipients or any other contraindications as given in the local SmPC for Dysport®
Key Trial Info
Start Date :
March 1 2013
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
February 6 2018
Estimated Enrollment :
302 Patients enrolled
Trial Details
Trial ID
NCT01840475
Start Date
March 1 2013
End Date
February 6 2018
Last Update
March 31 2020
Active Locations (5)
Enter a location and click search to find clinical trials sorted by distance.
1
Hermagor, Austria
2
Bidart, France
3
Berlin, Germany
4
Zwolle, Netherlands